Clinical trials
Lung clinical trials
Below are recruiting lung clinical trials, each written for real people, not researchers. We’re tracking 2,828 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06160596Recruiting
Understanding long-term cancer survival in hard-to-treat tumors
This study looks at why some people with hard-to-treat cancers live much longer than expected. It collects tumor samples to search for clues that might help future patients.
VillejuifAges 18 years+ - NCT06031181RecruitingPhase 3
Sublobar resection for early lung cancer found during surgery
This trial tests if a smaller surgery (sublobar resection) works well for patients with very early-stage lung cancer (adenocarcinoma in situ or minimally invasive adenocarcinoma) that is found during the operation. It may help avoid removing more lung tissue than necessary.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05689619Recruiting
Silibinin after one brain metastasis surgery for lung or breast cancer
This trial studies silibinin, a natural substance, to help prevent brain metastasis from coming back after surgery. It is for people with lung (NSCLC) or breast cancer who have exactly one small brain metastasis that is fully removed and has a specific lab marker in the brain tissue.
GenovaAges 18–70 - NCT07862777Recruiting
Predicting lung problems after major abdominal surgery in older adults
This study looks at whether a simple test from your blood and your physical health rating can help predict if you might have lung problems after a major surgery on your belly area. The goal is to help doctors plan better care for older patients during and after surgery.
Yenimahalle, AnkaraAges 65 years+ - NCT04938804Recruiting
One-time lung cancer screening with a low-dose chest CT
This study tests whether a one-time, low-dose chest CT scan can help find lung cancer early in certain people. You may be invited because of your age and location, and because you have not had recent related testing or symptoms.
Guangzhou, GuangdongAges 40–74 - NCT04235114RecruitingPhase 1/Phase 2
PET scan test for EGFR-positive cancers using an antibody tracer
This study tests a special PET scan agent (an antibody tracer) to help doctors see EGFR-positive cancers without needing invasive procedures. It is mainly for early testing (Phase 1/2) to understand how well it works for imaging.
Saskatoon, SaskatchewanAges 18–80 - NCT06203249Recruiting
Exploring lung health and immune system in a rare muscle disease
This trial looks at how the immune system and tiny organisms in the lungs may affect a rare condition called anti-MDA5 positive dermatomyositis, which can cause serious lung disease. It may help doctors understand why some patients get worse quickly and how to better treat them.
Beijing, Beijing MunicipalityAges 18–100 - NCT06198868Recruiting
MRD blood test to guide treatment in lung cancer
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
Nanjing, JiangsuAges 18 years+ - NCT05011487RecruitingPhase 2
Before-surgery osimertinib plus chemotherapy for EGFR lung cancer
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
Guangzhou, GuangdongAges 18–75 - NCT05191381Recruiting
Immune treatment using exosome therapy for severe COVID-19
This trial tests whether immune-supporting treatment made from exosomes can help people with critically severe COVID-19 and lung damage. If you qualify, you may receive this therapy as part of the study to see if it improves outcomes.
UlmAges 18–90 - NCT05824988Recruiting
Testing antibiotic dose levels for MAC lung infection
This trial studies how much medicine is needed (based on lab results) to treat MAC lung disease, an infection in the lungs. If you already have MAC and are receiving the recommended core antibiotics, your care may help researchers link treatment details to lab measurements.
ShanghaiAges 18 years+ - NCT06223906Recruiting
Heart valve disease marker study
This study will collect information and blood samples from people with heart valve disease to find biological markers that may help doctors better understand and treat the condition in the future.
Beijing, Beijing MunicipalityAges 18–100 - NCT06229340RecruitingPhase 2
Two drug combinations for advanced cancer with RAS mutations
This trial tests two different treatment combinations (leflunomide alone or with MEK inhibitor and hydroxychloroquine) in people with advanced cancer that has a RAS mutation and has not responded to at least two prior therapies.
Saint PetersburgAges 18–85 - NCT07874139Recruiting
Study on antibiotic resistance in chronic lung disease
This study looks at antibiotic resistance in people with chronic lung disease by checking their respiratory samples. It aims to understand how resistance develops and help improve treatment.
Ann Arbor, MichiganAges Any age - NCT05382728RecruitingPhase 3
Test drug for EGFR-mutant lung cancer without prior treatment
This Phase 3 trial studies TY-9591 in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR gene changes. It’s for those who haven’t had earlier medicines for advanced lung cancer, and it aims to see if the drug works better or safer than the comparison treatment.
Changsha, HunanAges 18–80 - NCT03225586Recruiting
Study of health differences in urban and rural communities
This study enrolls consenting adults to understand how health differs between people living in cities versus rural areas. Your participation may help researchers learn what factors influence health over time.
Rosario, Santa Fe ProvinceAges 35–70 - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT07863999RecruitingPhase 3
Immunotherapy before surgery for stage II-III lung cancer
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
Shanghai, ChinaAges 18 years+ - NCT06241807RecruitingPhase 2
Camrelizumab plus chemo before surgery for stage III lung cancer
This trial tests adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery for people with stage IIIA-IIIB non-small cell lung cancer. The goal is to see if this combination shrinks tumors more effectively before removal.
Jinan, ShandongAges 18–75 - NCT06262386Recruiting
Predicting lung cancer return after surgery
This study tests a new way to predict if non-small cell lung cancer will return after surgery. You will give blood samples to look for cancer cells, and the team will build a model to help plan better follow-up care.
Taoyuan CityAges 20–90 - NCT06271213Recruiting
Gut-lung study for children with breathing problems
This study looks at how the gut and lungs affect breathing problems in children. It compares samples from children with and without respiratory illnesses to understand why some children get sicker than others.
GlasgowAges birth–16 years - NCT05332925Recruiting
Tumor samples grown in dishes to predict immunotherapy response
This study takes small biopsy samples of your lung cancer and grows them in a dish to predict how well immunotherapy will work. If you qualify, you’ll receive standard immunotherapy (anti-PD-1/L1, with or without anti-CTLA-4), and the results from the dish-grown tumors will be compared to your real-world response.
Fairway, KansasAges 18–110 - NCT05775588Recruiting
Lung valve treatment for severe COPD
This study tests tiny valves placed in your airways to see if they improve your heart and muscle function over the long term. It's for people with severe COPD (chronic lung disease) and significant emphysema damage.
Beijing, Beijing MunicipalityAges 18–90 - NCT07870811Recruiting
Wellness program to improve quality of life after organ transplant
This study tests a program of exercise, education, and other non-drug activities to help people who have had an organ transplant feel better and improve their daily lives. It is for people who are at least one year past their transplant and have some quality-of-life concerns.
Palermo, PalermoAges 25–65
Hear when a new Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung?
- Yes. Clin2 currently lists 2,828 recruiting lung studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.